Mandraffino Giuseppe, Aragona Caterina Oriana, Basile Giorgio, Cairo Valentina, Mamone Federica, Morace Carmela, D'Ascola Angela, Alibrandi Angela, Lo Gullo Alberto, Loddo Saverio, Saitta Antonino, Imbalzano Egidio
Department of Clinical and Experimental Medicine, Internal Medicine, Italy.
Department of Clinical and Experimental Medicine, Internal Medicine, Italy.
Mech Ageing Dev. 2017 Jun;164:139-145. doi: 10.1016/j.mad.2017.03.003. Epub 2017 Mar 16.
Circulating progenitor cells (CPCs) represent a pool of cells capable of differentiating into mature cells of different organs and systems, promoting tissue maintenance and repair. Among CPCs, CD34+cells (CD34+CPCs) seem to predict outcome in CV disease, also in elderly people. A decline in CD34+CPCs was reported with advancing age. Moreover, aging is associated with a state of chronic inflammation, influencing life expectancy. Our purpose was to investigate a 10-year predictive ability of CD34+CPCs, inflammatory marker levels, classic CV risk factors (CVRFs), and Framingham Risk Score (FRS) in a population of healthy, self-sufficient octogenarians. We found that baseline CD34+CPCs was strongly associated with mortality, showing a significant difference in CD34+CPC numbers between deceased and living patients. Moreover, by dividing our patients into tertiles based on age reached, this difference was more remarkable the higher the age reached. Regressive analyses suggested that the chances of reaching an older age depend on higher CD34+CPCs at baseline and are not significantly affected by inflammatory markers levels, FRS, CVFRs, or HDL-C levels. We found that higher CD34+CPCs predict longer life also in the oldest old, providing additional insights on the predictive role of CD34+CPCs in subjects aged 80 years or more.
循环祖细胞（CPCs）是一类能够分化为不同器官和系统成熟细胞的细胞群，可促进组织维持和修复。在CPCs中，CD34+细胞（CD34+CPCs）似乎能预测心血管疾病的预后，在老年人中亦是如此。据报道，随着年龄增长，CD34+CPCs数量会下降。此外，衰老与慢性炎症状态相关，影响预期寿命。我们的目的是研究在健康、自理的八旬老人群体中，CD34+CPCs、炎症标志物水平、经典心血管危险因素（CVRFs）和弗雷明汉风险评分（FRS）的10年预测能力。我们发现，基线CD34+CPCs与死亡率密切相关，死亡患者和存活患者的CD34+CPCs数量存在显著差异。此外，根据达到的年龄将患者分为三分位数，达到的年龄越高，这种差异越显著。回归分析表明，达到较高年龄的机会取决于基线时较高的CD34+CPCs数量，且不受炎症标志物水平、FRS、CVFRs或高密度脂蛋白胆固醇（HDL-C）水平的显著影响。我们发现，较高的CD34+CPCs数量在高龄老人中也预示着更长的寿命，这为CD34+CPCs在80岁及以上人群中的预测作用提供了更多见解。
